Molecular Partners AG ADR (MOLN) - Total Assets
Based on the latest financial reports, Molecular Partners AG ADR (MOLN) holds total assets worth $112.15 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MOLN net assets for net asset value and shareholders' equity analysis.
Molecular Partners AG ADR - Total Assets Trend (2013–2024)
This chart illustrates how Molecular Partners AG ADR's total assets have evolved over time, based on quarterly financial data.
Molecular Partners AG ADR - Asset Composition Analysis
Current Asset Composition (December 2024)
Molecular Partners AG ADR's total assets of $112.15 Million consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.3% |
| Accounts Receivable | $286.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $49.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Molecular Partners AG ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Molecular Partners AG ADR (MOLN) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Molecular Partners AG ADR's current assets represent 97.3% of total assets in 2024, a decrease from 97.9% in 2013.
- Cash Position: Cash and equivalents constituted 40.3% of total assets in 2024, down from 87.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Molecular Partners AG ADR Competitors by Total Assets
Key competitors of Molecular Partners AG ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Molecular Partners AG ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.28 | 14.33 | 3.08 |
| Quick Ratio | 9.28 | 14.33 | 3.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $97.22 Million | $139.10 Million | $120.14 Million |
Molecular Partners AG ADR - Advanced Valuation Insights
This section examines the relationship between Molecular Partners AG ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 1.04 |
| Asset Growth Rate (YoY) | -20.1% |
| Total Assets | $158.53 Million |
| Market Capitalization | $164.56 Million USD |
Valuation Analysis
Above Book Valuation: The market values Molecular Partners AG ADR's assets above their book value (1.04x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Molecular Partners AG ADR's assets decreased by 20.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Molecular Partners AG ADR (2013–2024)
The table below shows the annual total assets of Molecular Partners AG ADR from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $158.53 Million | -20.08% |
| 2023-12-31 | $198.35 Million | -24.37% |
| 2022-12-31 | $262.26 Million | +51.89% |
| 2021-12-31 | $172.67 Million | -7.93% |
| 2020-12-31 | $187.55 Million | +78.73% |
| 2019-12-31 | $104.94 Million | -32.37% |
| 2018-12-31 | $155.16 Million | +7.43% |
| 2017-12-31 | $144.42 Million | -21.55% |
| 2016-12-31 | $184.10 Million | -16.09% |
| 2015-12-31 | $219.40 Million | +13.08% |
| 2014-12-31 | $194.02 Million | +76.20% |
| 2013-12-31 | $110.11 Million | -- |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more